PL 28452

Drug Profile

PL 28452

Alternative Names: PLD 177; PLR 13

Latest Information Update: 15 Aug 2007

Price : $50

At a glance

  • Originator PLIVA d.d.
  • Class Anti-inflammatories; Antiasthmatics
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 13 Apr 2005 Preclinical trials in Chronic obstructive pulmonary disease in Croatia (Inhalation)
  • 12 Dec 2003 Preclinical trials in Asthma in Croatia (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top